Pharmacodynamics 
kidney stone
EVENTS, EVENT, KIDNEY STONE
In the primary analysis, no participants in the mITT had a > 30% reduction from baseline in mean 24-h Uox excretion over two consecutive visits. In sensitivity analyses, one participant met the efficacy endpoint of > 30% reduction in mean 24-h Uox excretion over two consecutive visits when BSA-adjusted Uox was used for all participants. No participants met the endpoint when completeness criteria or LOCF imputation methods were used.Figure Individual changes in 24-h Uox excretion from baseline to Day 85 after single-dose administration of nedosiran or placebo (mITT population). Mean (± SD) change from baseline to Day 85 in 24-h urinary oxalate-to-creatinine ratios were −28.5 (± 27.4) mmol/mol in the nedosiran group and 11.5 mmol/mol in the placebo group (Fig. S2). There were no clinically relevant changes from baseline to Day 85 in individual concentrations of 24-h urinary citrate, calcium, phosphate, and magnesium (Fig. S3).One participant (25%) in the nedosiran group and one participant (50%) in the placebo group had kidney stone events during the study. There was one stone event in the nedosiran group and three stone events in the placebo group, of which two were concurrent (i.e., occurring in the same 4-week period).